Skip to main content
. Author manuscript; available in PMC: 2017 Sep 10.
Published in final edited form as: Mod Pathol. 2017 Mar 10;30(7):1032–1041. doi: 10.1038/modpathol.2017.15

Figure 1.

Figure 1

Recurrence-free survival for endometrioid endometrial cancer patients, grade 1–2 and stage I–II, by CTNNB1 mutation status (A), TP53 mutation status (B), and combined CTNNB1 and TP53 mutation (C). Presence of mutation in CTNNB1 or TP53 is associated with worse recurrence-free survival in this subset of endometrial cancer patients.